The FDA has cleared Allogene Therapeutics' IND application for ALLO-329, a novel dual-targeting CAR T cell therapy designed to treat multiple...
Tune Therapeutics has announced regulatory approval to begin a Phase 1b trial of its chronic hepatitis B therapy in Hong Kong, marking a strategic...
Korro Bio has received clearance from the Australian regulatory body to initiate a Phase 1/2 trial of its RNA-editing therapeutic candiate KRRO-110 in...
Tune Therapeutics has received clinical trial application approval from the New Zealand Medicines and Medical Devices Safety Authority to initiate a...
The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...
In this clinical update, we bring you the latest news from four gene-editing trials sponsored by RenJi Hospital (Shanghai), The University of Texas MD...
Last week, Vor Bio announced new, encouraging clinical data from the ongoing Phase 1/2 VBP101 trial of trem-cel followed by the anti-CD33...
YolTech Therapeutics announced last week that the first two patients have been dosed in a Phase 1 trial of YOLT-203, an in vivo CRISPR-based...
